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Adherence to Treatment in Severe Asthma
Predicting Factors in a Program for Asthma Control in Brazil
Adelmir Souza-Machado, MD, Pablo Moura Santos, MSc, and Álvaro A. Cruz, MD
Background: In Brazil, like many other low- to middle-income coun-
tries, most asthmatic patients cannot afford the medication necessary to
prevent exacerbations. The reference clinic of the Programme for
Asthma Control in Bahia (ProAR; Salvador-Bahia) offers free medical
care, pharmaceutical assistance (inhaled medication) and patient edu-
cation. The reference clinic is accessible to all the population of
Salvador and the Programme is targeted on severe asthma.
Objective: The aim of the present study was to evaluate adherence
to inhaled medication in severe asthmatics enrolled in ProAR.
Methods: A sub-group of 160 consecutive severe asthmatics en-
rolled in ProAR were followed prospectively for 6 months. All
patients were assessed by means the Asthma Control Questionnaire,
the Beck Depression Inventory and spirometry. The rate of adher-
ence to inhaled corticosteroid was checked monthly. A cut-off point
of 80% of the doses prescribed in the period was used to define
patients as adherent.
Results: Of the one hundred-sixty patients with severe asthma
included, it was possible to objectively assess adherence to the use
of the inhaled corticosteroid in 158. Among these, 112 (70.9%) were
considered adherent according to the adopted cut-off point. The rate
of adherence in the whole sample of subjects was 83.9% of the
prescribed doses. There was a significant association between asthma
control and adherence to treatment. Predictors of poor adherence were
adverse effects, living far from the referral center, limited resources to
pay for transportation and dose schedule.
Conclusion: In the present study, adherence to treatment was high.
In a sample of patients with severe asthma managed in a public
program that provides free medication and multidisciplinary treat-
ment at a referral center, adherence to treatment was found to be
associated with favorable clinical outcomes.
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Asthma is a chronic inflammatory disease characterized bysymptoms such as dyspnea, chest tightness, wheezing,
and cough. The goals of asthma treatment are (1) control of
the clinical manifestations and (2) improvement in lung
function.1
There is evidence that reducing inflammation with
therapy leads to clinical control. Inhaled corticosteroids are
the most effective controller medications currently available.1
However, asthma management and symptoms’ control are
not so easy to obtain. According to the World Health Orga-
nization, the definition of adherence is “the extent to which
person’s behavior—taking medication, after a diet and exe-
cuting lifestyle changes, corresponds with agreed recommen-
dations from a health care provider”.2
Adherence to treatment is one of the most important
factors that guarantees the success of the asthma treatment.
Several factors may influence adherence to treatment and
asthma control such as patients’ knowledge about their dis-
ease, cultural and socioeconomic aspects, poor perception of
asthma symptoms, adverse events, and skills in use inhaler
devices.3–7 In addition, compliance with medical prescrip-
tions tends to decline steeply over time.8 Patients with
chronic diseases in high-income countries frequently do not
use their medications as recommended by clinicians. In low-
and middle-income countries, nonadherence is more critical
because of the mix of limited access to health care, lack of
appropriate diagnosis, and low availability or affordability of
essential medicines.8
The aim of this study was to review adherence and
nonadherence to treatment patients with asthma, with empha-
sis on our experience in a reference center for control of
severe asthma in Brazil.
METHODS
Reference Center of the Programme for
Control of Asthma in Bahia (ProAR)
The reference clinic of the Programme for Asthma
Control in Bahia (ProAR; Salvador-Bahia) offers free medi-
cal care, pharmaceutical assistance (inhaled medication), and
patient education. The reference clinic is accessible to all the
population of Salvador and the program is targeted for severe
asthma. The patients use combined inhaled corticosteroid
(beclomethasone or budesonide) and a long-acting 2 agonist
(formoterol) for maintenance and also a short-acting inhaled
2 agonist (fenoterol) for rescue.1 Additionally, patients and
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their families receive educational classes and multidisci-
plinary care by members of our team: pharmacists, nurses,
psychologist, and clinicians.
A preliminary study comparing patients with severe
asthma 1 year before and 1 year after admission to ProAR
demonstrated that such intervention markedly reduced
asthma morbidity in above 80% of these individuals.9 (Ta-
ble 1). This result suggests that regular use of prescribed
medication was achieved.
Study Design and Patients’ Assessment
A subgroup of 160 consecutive patients with severe
asthma enrolled in ProAR were followed prospectively for 6
months for objective quantification of their adherence to
inhaled medication. Data about socioeconomic and demo-
graphic characteristics, history of asthma, severity of the
symptoms based on the Asthma Control Questionnaire,10
medications used, symptoms of depression (assessed by mean
Beck Depression Inventory)11 and beliefs, acceptance of the
disease, knowledge of the benefits and risks of the treatment,
and degree of communication with the health professionals
who monitored the patient were collected. Patients also un-
derwent pulmonary function tests (spirometry) for evaluation
of the functional response to treatment.
At the end of each monthly visit, the patients received
sufficient medication to use until the next visit, were in-
structed to fill a register with the missed doses, and return the
packages of the medication dispensed in the previous visit.
Powder capsules/inhalers returned were counted or weighed.
The rate of adherence to the inhaled corticosteroid (IC)
treatment was calculated as follows:
Y For the ICs in capsule presentation, the following for-
mula was used: (NU  NT)  100, where NU is the
number of capsules actually used during the period and
NT is the number of capsules that should have been
used.
Y For the ICs in dry powder presentation for oral inhala-
tion, the inhalers where weighed at the time of dispens-
ing and after 30 days of use, at which point the following
formula was used: (U  T)  100, where U is quantity
(in g) actually used during the period and T is the
quantity (in g) that should have been used.
At the end of the follow-up period, the pharmacy
database was analyzed to compare it with the information
collected by the research assistants, and to determine the
dates of patient visits and the quantity of medication dis-
pensed at each visit. A cut-off point of 80% of the doses
prescribed in the period was used to define patients as
adherent. This value was adopted taking into consideration
the severity of the disease and the availability of free medi-
cation to all of the patients treated via the ProAR.
Ethical Aspects
The study design and procedures were approved by
the Ethics Committee for Research of the Federal Univer-
sity of Bahia School of Medicine. All patients gave written
informed consent, and their identification data were main-
tained confidential.
Statistics
Data were analyzed using the Statistical Package for the
Social Sciences, version 9.0 (SPSS Inc., Chicago, IL, USA).
The mean and SD were calculated for the quantitative vari-
ables that presented normal distribution.
Categorical variables were presented as frequency and
proportion. The 2 test was used for the evaluation of the
statistical significance among categorical variables and the
Student’s t test was used for the comparison among the means
of the quantitative data. The Mann-Whitney U test and the
Kruskal-Wallis test were used for the analysis of quantitative
variables presenting asymmetric data. The logistic regression
model was used for adjusting potential confounding factors.
The level of statistical significance was set at  0.05.
The degree of association among the studied variables was
evaluated using odds ratios with a confidence interval of 95%.
The calculation of the sample size was based on the
following premises: total number of ProAR patients during
the period (approximately 1600 patients); relative margin of
error of 5%; confidence interval of 95%; prevalence of
adherence of approximately 50%, based on data found in the
literature; power of 80%; significance level of 5%; and a
possibility of 20% loss to follow-up together, which indicated
the ideal sample size to be 156 patients.
RESULTS
General Features of the Sample Followed Up
Of the 160 patients with severe asthma included (Ta-
ble 2), it was possible to objectively assess adherence to the
use of the inhaled corticosteroid prescribed in 158 patients.
Among these, 112 (70.9%) were considered adherent accord-
ing to the adopted cutoff point. The rate of adherence in the
entire sample of subjects was 83.9% of the prescribed doses.
There was no difference in the mean age among the
groups of adherent and nonadherent patients (49.7 and 46.8
years, respectively; P 0.2). The mean duration of asthma in
the studied sample was 26.0  15.8 years, with a median of
26 years. The adherent patients had a longer asthma history in
TABLE 1. Utilization of Health Resources 1 Year Before and
1 Year After Admission in a Reference Centre for Asthma
Control (ProAR) in Salvador-Bahia, Brazil: Analysis of a






Oral corticosteroid cycles N  1281 N  421 0.01
4.7 per patient 1.6 per patient
Absenteeism with work (days) N  3056 N  431 0.01
11.4 per patient 1.6 per patient
Visits to an emergency room N  8577 N  1289 0.01
31.9 per patient 4.8 per patient
Hospitalizations N  383 N  38
1.42 per patient 0.14 per patient 0.01
Reproduced with permission from J Bras Pneumol.9
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relation to nonadherent patients (27.8 and 22.1 years, respec-
tively; P  0.043; 95% CI: 0.18–11.19).
The rate of adherence of the patients residing in the city
of Salvador compared with the patients residing outside
Salvador was respectively 85.0% and 78.1%. (P 0.01; 95%
CI: 1.3–12.4).
Eighteen patients (11.3%) reported having limited re-
sources to pay for transportation in the days scheduled for
consultation. These patients presented lower adherence in
relation to the other patients of this cohort (P  0.013). The
risk of nonadherence to treatment was 3.6 times higher
among patients without resources for paying the fare for
transportation (95% CI: 1.3–9.8).
Asthma Control
There was a significant association between asthma
control and adherence to treatment. According to the Asthma
Control Questionnaire (ACQ), 60 patients (38%) pre-
sented controlled asthma. ACQ scores were lower among
adherent patients in comparison to nonadherent patients (1.6
versus 2.3; P  0.008). Rate of adherence was higher among
patients with controlled asthma in comparison to those with
uncontrolled asthma (88.5% vs 80.9%; P  0.008) The
estimated risk of uncontrolled asthma was 2.9 times higher
among nonadherent patients than among adherent patients
(95% CI: 1.3–6.4).
Predictors of Poor Adherence
Predictors of poor adherence were adverse effects,
living far from the referral center, limited resources to pay for
transportation, and dosing schedule (Table 3). Other factors
of concern, such as symptoms of depression, religion, and
economic status, were not associated with poor adherence in
our study.
Visits to Emergency Room
Fifty-one of 158 patients (32%) reported emergency
room visits in the course of the follow-up (mean  SD 
3.2  2.6 visits), and 18 (35%) of them were considered
nonadherent to the treatment. One hundred seven patients
(68%) did not visit the emergency room in the time period. Of
those, 28 (26%) were considered nonadherent to the treat-
ment. However, the overall adherence to treatment was not
statistically different between groups who visited (81.5%)
and did not visit (85.7%) the emergency room (P 0.08) and
the number of emergency room visits was not statistically
different between adherent and nonadherent patients (0.9 
1.9 vs 1.4  2.6 visits, respectively; P  0.2).
Scheduled Doses of Inhaled Steroids
Inhaled corticosteroids were used 1 to 3 times a day:
123 (77.8%) patients used medication twice a day, 34
(21.5%) 3 times a day, and 1 (0.7%) only once a day. The
mean daily dose of corticosteroids was 870  200 g
(median, 800 g), varying between 400 and 1600 g. Ad-
herence to treatment was significantly lower among patients
who used the IC 3 times a day than among those who used it
2 times a day (78.9% and 85.2%, respectively; P  0.02;
OR  0.34; 95% CI: 0.22–0.68).
Adverse Events
Thirty-one (19.6%) patients reported adverse events
after the use of inhaled medication. We observed an inverse
association between the presence of adverse events and ad-
herence to pharmacological treatment (P  0.017). The
estimated risk of nonadherence was 33% higher among pa-
tients who presented adverse events in the present study (95%
CI: 0.1–0.7) in comparison to the patients who reported no
adverse events. The adverse events most frequently reported
by the patients were the following: epigastric pain in 3
patients; weight gain and heartburn in 2; and stomach acidity,
agitation, conjunctivitis, oral candidiasis, pharyngeal irritation,
TABLE 2. Socio-biologic Characteristics of the Sample of
Severe Asthmatics From ProAR Studied Objectively
for Adherence
Characteristic Results (%) Adherence (%) P
Gender
Male 40 (25%) 84.1 0.8
Female 120 (75%) 83.7
Age (years), mean  SD 49  13.9
No. children 2.7
Religion, n (%)
Catholic 94 (58.8%) 85.2 0.1
Protestant 34 (21.3%) 81.1
Other 30 (19.9%) 83.8
Permanent address 153 (95.6%) 83.8 0.4
Marital status, n (%)
Married 75 (46.9%) 81.4 0.2
Single 46 (28.8%) 85.2
Divorced 23 (14.4%) 86.4
Widow/widower 16 (10%) 87.6
Employment status, n (%)
Employed 49 (30.6%) 78.4 0.7
Unemployed 31 (19.4%) 89.1
Retired 37 (23.1%) 85.3
Housewife 39 (24.4%) 84.3
Level of education, n (%)
Illiterate 15 (9.4%) 84.8 0.7
Junior high 89 (55.6%) 84.1
High school 52 (32.5%) 83.1
University 4 (2.5%) 83.9
Reproduced with permission from J Bras Pneumol.7
TABLE 3. Multivariate Analyses of the Variables Found as




Regression 95% IC P
Residing outside Salvador 4.1 1.5–11.2 0.004
Longer duration of asthma 0.9 0.9–1.0 0.06
Occurrence of adverse event 3.9 1.3–11.5 0.01
Dose schedule: twice a day 5.8 2.2–14.8 0.0002
Transportation difficulties 4.0 1.3–12.8 0.017
Reproduced with permission from J Bras Pneumol.7
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nausea, throat clearing, hoarseness, drowsiness, tachycardia,
dizziness, tremors, blurred vision, and xerostomia in 1.
Depressive Symptoms
Depressive symptoms were assessed by using Beck
Depression Inventory (BDI). The mean  SD for BDI score
was 13.4  10.0 (median, 11 points), and 54 individuals
(33.8%) were classified as having depressive symptoms,
scoring more than 20 points on the BDI. There was no
significant association between adherence to treatment and
depressive symptoms (P  0.23). The rate of adherence was
similar in both groups of patients (83%; P  0.9).
Other Factors Studied and Not Associated
With Adherence
In a logistic regression analysis adjusted for the vari-
ables that were considered statistically significant in the
bivariate analysis, such as difficulty in communication with
pharmacist and physician, access to medical assistance, reli-
gious and philosophical concerns, social embarrassment of
using medication, and forgetfulness for using another medi-
cine, we did not find statistically significant differences for
any of the variables tested.
Only 14 patients (8.8%) reported having difficulty in
understanding the information given by the physician and
pharmacist who monitored them. The rate of adherence to
treatment among those patients was 82.6%, and there was no
significant difference between them and the other patients
(P  0.7). As for the access to medical assistance, 7 patients
(4.4%) reported having difficulty in scheduling extra appoint-
ments when necessary. Among those patients, adherence to
treatment was 85%, no different from the other participants
(P  0.8).
DISCUSSION
The present study showed the patients monitored in
ProAR presented a high rate of adherence to asthma treatment
(83.9%). Similar studies showed frequencies that vary from
30% to 70%.12 In a national multicenter study that evaluated
131 people with asthma, Chatkin et al observed asthma
therapy adherence in 51.9% of the patients.4
One of the aspects of the present study that should be
taken into consideration is that we observed good communi-
cation between patients and the health team who worked in
ProAR, together with easy and rapid patient access to medical
care and to extra appointments. In a study using different
parameters to evaluate adherence to treatment,13 patient
satisfaction was the only factor significantly associated
with adherence. In the present study, those aspects related
to an empathic relationship between patients and health
professionals contributed to compliance with pharmaco-
logical treatment.
Various factors can be considered predictors of nonad-
herence to treatment in patients with asthma. Poor knowledge
of disease, lack of access to medication, difficulties in the
understanding of proper medication use, and inhaler tech-
niques contribute significantly to this problem, especially in
low-income settings. In Lagos, Nigeria, specialists evaluated
106 patients with uncontrolled asthma and concluded that14
the majority of the people with asthma did not receive any
health education about their disease after consultation and
52.8% had poor inhaler technique. In the present study, we
found an association between nonadherence to treatment and
the following variables: adverse events; living far from the
health facility; limited resources to pay the public transpor-
tation; and multiple daily doses. Asthma was better controlled
in patients presenting higher adherence. In the present study,
we were unable to evaluate the relationship between adher-
ence to treatment and the different classifications of the
severity of asthma because all patients selected had severe
persistent asthma.1
Depressive symptoms, as evaluated by the Beck De-
pression Inventory, presented no association with poor ad-
herence to treatment. It is of note that the frequency of such
symptoms was elevated among the asthma patients in the
present study. The adopted cutoff point (20 points) for the
evaluation of the depressive symptoms was more conserva-
tive than the one adopted in other studies in which the
prevalence of depressive symptoms is high. This result
differs from the findings of other studies in which depres-
sion has been associated with low adherence to treat-
ment.15 Corroborating our results, other studies showed a
relatively high frequency of depressive symptoms in pa-
tients with more severe disease and presenting a low
response to the treatment.16,17
We used 3 different methods to assess adherence:
pharmacy database records, counting or weighing medica-
tion, and diary registration. Therefore, overestimation of
medication use was objectively evaluated.
Our study aimed to analyze adherence to treatment in a
sample of patients with severe asthma who participated in a
multiprofessional program of outpatient management, with
free medication available. Consequently, the rates of adher-
ence found in the present study cannot be extrapolated to the
population in general because some predictors of adherence,
such as the costs of the medication acquisition and of medical
appointments, which can influence the pattern of their use, are
not part of the scenario for the patients enrolled in this
program. The use of inhaled corticosteroids contributes ef-
fectively and safely to the control of persistent asthma.
Adherence to therapy is crucial to the success of the treat-
ment. Studies of adults and children have shown that some
50% of those on long-term therapy fail to take medications as
directed. Complete discontinuation of the asthma treatment
will probably result in clinical deterioration and exacerbation
and may contribute to poor clinical outcomes.13,18,19 In the
present study, the rate of nonadherence to treatment was
higher among patients who had visited the emergency room.
Although this difference did not rise to the level of statistical
significance, there was a tendency toward a positive associ-
ation between the number of visits to the emergency room
and nonadherence, reflecting the inadequate asthma control
among such patients.
The treatment regimen can influence the pattern of
adherence. Our results confirm that patients that were
prescribed a treatment regimen of 2 inhalations daily
adhere more to treatment than those prescribed 3 daily
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inhalations. This result corroborates the findings of a
systematic review of 76 clinical trials in which adherence
was found to be inversely proportional to the frequency of
daily doses.20
Patient’s apprehension about side effects of inhaled
glucocorticosteroids may influence adherence in general and
the number of doses effectively taken in a given day.
In a Brazilian survey, Chatkin et al observed adherence
to asthma therapy in 51.9% of individuals. The authors also
showed that the most severe asthma symptoms were associ-
ated with higher adherence to asthma therapy.4 The reasons
for patient’s nonadherence are complex and are frequently
related to patients themselves, health care professionals, the
health care system, medications, and inhalation devices.
In the present study, the adverse events reported by the
patients constituted another factor associated with low adher-
ence to treatment. However, we did not observe corticoste-
roid phobia, which has been described in other studies, as a
determining factor for adherence to treatment.21 Although we
found that a large number of patients feared the potential side
effects of their medication, all patients stated that they con-
sidered the correct administration of the medication impor-
tant. Furthermore, only half of these patients reported expe-
riencing some adverse event which made it difficult to
continue using the medication. Therefore, in our study, the
patients failed to take their medication when they actually
presented some adverse reaction to the medication.
The present study has some limitations in relation to its
external validity, as mentioned before. We cannot extrapolate
our results to the general population.
Another limitation of the study is the possible selection
bias. By including the patients consecutively, we risk select-
ing only patients who came to the visits regularly, and it was
therefore impossible to identify and interview the patients
who missed visits. Nevertheless, during the study, adherence
was evaluated prospectively and objectively, as were the
many possible predictors of adherence, in patients with se-
vere asthma.
Poor adherence is common and is closely associated
with asthma morbidity. Nonadherence to treatment is not
simply the result of a patients’ deficiency. Better adherence
results from overcoming obstacles such as access to medica-
tion, understanding of disease and its management, easy
communication between health professionals and patients,
and education programs fitted to health providers, patients,
and their families.
CONCLUSIONS
In a sample of patients with severe asthma managed by
a public program that provides free medication and multidis-
ciplinary treatment at a referral center, adherence to treatment
was high and found to be associated with the clinical response
to treatment. The most relevant predictors of poor adherence
were living far from the clinic, limited resources for trans-
portation, occurrence of adverse events, and daily multidose
prescription.
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